Literature DB >> 34853020

Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in California.

David J Press1,2,3, Salma Shariff-Marco4,5,6, Daphne Y Lichtensztajn4,5, Diane Lauderdale7, Adam B Murphy8, Pushkar P Inamdar5, Mindy C DeRouen4,5,6, Ann S Hamilton9, Juan Yang4,5, Katherine Lin4,5, Donald Hedeker7, Christopher A Haiman9, Iona Cheng4,5,6, Scarlett Lin Gomez4,5,6.   

Abstract

BACKGROUND: Black men are more likely than Non-Hispanic White (NHW) men to be diagnosed with high-risk prostate cancer. We examined the extent to which social factors were associated with differences in prostate cancer risk profiles between Black men and NHW men [using a modification to the original D'Amico risk groups based on prostate specific antigen (PSA), Gleason score (GS), and TNM stage (stage)], based on individual and combined clinicopathologic characteristics.
METHODS: We conducted a cross-sectional population-based study of 23,555 Black men and 146,889 NHW men diagnosed with prostate cancer in the California Cancer Registry from 2004 to 2017. We conducted multivariable logistic regression to examine the association of year of diagnosis, block group-level neighborhood socioeconomic status (nSES), marital status, and insurance type on differences in prostate cancer risk profiles between Black and NHW men.
RESULTS: High PSA (>20 ng/mL), GS, stage, individually and combined prostate cancer risk profiles were more common among Black men versus NHW men. In fully adjusted models, relative to NHW men, we observed a persistent 67% increased odds of high PSA among Black men. nSES was the factor most strongly associated with racial disparity in high PSA, accounting for 25% of the difference. Marital status was the factor that was second most associated with a racial disparity.
CONCLUSIONS: nSES was the factor most strongly associated with racial disparities in high PSA prostate cancer. IMPACT: The influence of nSES on racial disparities in PSA, GS, stage, and prostate cancer risk profiles warrants further consideration. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34853020      PMCID: PMC8825684          DOI: 10.1158/1055-9965.EPI-21-0697

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  47 in total

1.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.

Authors:  K Yost; C Perkins; R Cohen; C Morris; W Wright
Journal:  Cancer Causes Control       Date:  2001-10       Impact factor: 2.506

2.  Scaling regression inputs by dividing by two standard deviations.

Authors:  Andrew Gelman
Journal:  Stat Med       Date:  2008-07-10       Impact factor: 2.373

Review 3.  Prostate-specific antigen concentration in young men: new estimates and review of the literature.

Authors:  Siobhan Sutcliffe; Ratna Pakpahan; Lori J Sokoll; Debra J Elliott; Remington L Nevin; Steven B Cersovsky; Patrick C Walsh; Elizabeth A Platz
Journal:  BJU Int       Date:  2012-04-13       Impact factor: 5.588

4.  Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; C K Naughton; M K Brawer; R C Flanigan; J P Richie; A Patel; P C Walsh; P T Scardino; P H Lange; J B deKernion; P C Southwick; K G Loveland; R E Parson; G H Gasior
Journal:  Urology       Date:  2000-03       Impact factor: 2.649

5.  Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.

Authors:  Maria J Schymura; Leon Sun; Antoinette Percy-Laurry
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

6.  Prostate Cancer, Version 1.2016.

Authors:  James L Mohler; Andrew J Armstrong; Robert R Bahnson; Anthony Victor D'Amico; Brian J Davis; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric M Horwitz; Michael Hurwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Richard J Lee; Joshua J Meeks; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ted A Skolarus; Eric J Small; Guru Sonpavde; Sandy Srinivas; Seth A Strope; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2016-01       Impact factor: 11.908

7.  Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.

Authors:  T Malati; G Rajani Kumari; P V L N Murthy; Ch Ram Reddy; B Surya Prakash
Journal:  Indian J Clin Biochem       Date:  2006-03

8.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Authors:  J W Moul; I A Sesterhenn; R R Connelly; T Douglas; S Srivastava; F K Mostofi; D G McLeod
Journal:  JAMA       Date:  1995-10-25       Impact factor: 56.272

9.  Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Authors:  Blase N Polite; Lucile L Adams-Campbell; Otis W Brawley; Nina Bickell; John M Carethers; Christopher R Flowers; Margaret Foti; Scarlett Lin Gomez; Jennifer J Griggs; Christopher S Lathan; Christopher I Li; J Leonard Lichtenfeld; Worta McCaskill-Stevens; Electra D Paskett
Journal:  J Clin Oncol       Date:  2017-07-24       Impact factor: 44.544

10.  Use of professional and informal support by African Americans and Caribbean blacks with mental disorders.

Authors:  Amanda Toler Woodward; Robert Joseph Taylor; Kai McKeever Bullard; Harold W Neighbors; Linda M Chatters; James S Jackson
Journal:  Psychiatr Serv       Date:  2008-11       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.